Thu, Aug 21, 2014, 2:55 AM EDT - U.S. Markets open in 6 hrs 35 mins

Recent

% | $
Quotes you view appear here for quick access.

InVivo Therapeutics Corp Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • hgff101 hgff101 May 10, 2012 10:31 AM Flag

    Frank Spank

    The several planned trials could go either way. Success or failure.

    So what makes you use the word "inevitable"

    Are you certain the trials will fail?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Of course I'm not certain about the trials failing, or succeeding, for that matter. What is inevitable is that the market will come to realize that a preclinical-stage company focused on a single indication with a market size of maybe 200MM with a bumbling fool of a CEO is not worth $150MM and you'll all go down to $0.25 pps. Look at comps. Someone provide me their idea of a comp biotech so we can engage in a conversation on valuation. No one will do that. Anyone? Anyone?

      • 2 Replies to tdarren36
      • Some major investment company just invested $20 million into the company at $2.10 that is a market cap of around $130 million....seems they believe this company is worth it!! We will find out which company bought those 10 million shares during the trials!

      • I had the exact same concerns while looking at the company - or if looking at any early stage bio-device development-stage company.

        However, they make a compelling case that the development stage has great potential for progressing at a much faster rate than would be the generic expectation.

        If the first indication has a peak market size of just 200mm as you assert, that alone would support an eventual company valuation of 500mm.

        The company's market size projection is much larger than yours. The actual size potential probably lies somewhere between the two.

 
NVIV
0.67-0.03(-4.67%)Aug 20 3:58 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.